BASHH Syphilis Guidelines 2024: Key Updates & Treatment
Explore the updated BASHH syphilis guidelines for 2024. Learn about diagnosis, treatment, and management of syphilis in adults and pregnancy.
BASHH Syphilis Guidelines 2024: A Comprehensive Guide to Diagnosis and Treatment
Table of Contents
- What Are the BASHH Syphilis Guidelines?
- Why Were the 2024 Guidelines Updated?
- Diagnosis and Staging of Syphilis
- Recommended Treatment Protocols
- Special Populations: Pregnancy and Neurosyphilis
- Prevention, Partner Notification, and Follow-up
- Frequently Asked Questions (FAQ)
Syphilis, a sexually transmitted infection (STI) caused by the bacterium Treponema pallidum, has seen a concerning global resurgence. In this complex landscape, clear, evidence-based clinical guidance is paramount. The BASHH syphilis guidelines serve as the gold standard for healthcare professionals in the UK, providing a critical framework for managing this multifaceted disease. This comprehensive guide breaks down the key updates from the 2024 BASHH syphilis guidelines, explaining what they mean for diagnosis, treatment, and public health. You'll learn about the latest treatment protocols, the crucial management of syphilis in pregnancy, and how modern approaches are tackling challenges like neurosyphilis.
What Are the BASHH Syphilis Guidelines?
The British Association for Sexual Health and HIV (BASHH) is the leading professional body for sexual health in the UK. Its guidelines are developed by expert committees through rigorous review of the latest clinical evidence. The BASHH syphilis guidelines are not just a document; they are a dynamic, evidence-based stream of best practices designed to standardize care, improve patient outcomes, and curb the spread of infection. The 2024 update, led by Kingston and colleagues, reflects significant advancements in our understanding of the disease, particularly in the context of rising case numbers among various demographic groups, including GBMSM (gay, bisexual, and other men who have sex with men) and, increasingly, heterosexual populations.
"Clinical guidelines must evolve with the epidemiology of disease. The 2024 update addresses the real-world complexities we face today, from managing latent cases to preventing congenital syphilis, ensuring every patient receives the most effective care based on current science." – Illustrative expert opinion on guideline development.
Why Were the 2024 Guidelines Updated?
The need for updated BASHH syphilis guidelines was driven by a stark reality: a sustained and troubling increase in syphilis cases. This isn't a historical relic but a modern public health challenge. Factors include changes in sexual behaviour, the use of pre-exposure prophylaxis (PrEP) for HIV (which may lead to reduced condom use), and improved but complex testing methodologies. The guidelines incorporate new research, such as studies on optimal penicillin dosing and the management of neurosyphilis, ensuring recommendations are grounded in the most recent data. The parallel publication of specific guidelines for syphilis in pregnancy and child underscores the critical importance of preventing mother-to-child transmission, a devastating but entirely preventable outcome.
The Rising Tide of Cases
Syphilis is often called "the great imitator" due to its wide range of symptoms. The primary stage typically features a single, painless chancre at the site of entry (e.g., genital, oral, or extra-genital), but this can be missed. Left untreated, it progresses to secondary syphilis, which can involve rash, fever, and lymph node swelling, and eventually to latent and tertiary disease with severe complications. This progression makes timely diagnosis and treatment, as outlined in the guidelines, absolutely essential.
Diagnosis and Staging: The Cornerstone of Management
Accurate diagnosis and correct staging are the first critical steps in managing syphilis, as they directly determine the treatment pathway. The BASHH syphilis guidelines provide a clear algorithm for clinicians.
- Serological Testing: The mainstay of diagnosis. This involves a combination of non-treponemal tests (e.g., RPR, VDRL) that measure disease activity and treponemal tests (e.g., EIA, TPHA) that confirm exposure. The pattern of results helps determine if an infection is likely early (acquired within the last 2 years) or late.
- Clinical Assessment: A thorough history and examination to identify symptoms of primary (chancre) or secondary (rash, mucosal involvement) syphilis.
- Staging: Syphilis is staged as:
- Early Infectious Syphilis: Primary, secondary, or early latent (< 2 years duration). This stage is highly transmissible.
- Late Syphilis: Late latent (>2 years or unknown duration) or tertiary (involving heart, brain, etc.).
The guideline emphasizes that neurosyphilis can occur at any stage. Cerebrospinal fluid (CSF) examination is recommended in specific scenarios, such as neurological symptoms, treatment failure, or HIV co-infection with late latent syphilis, a point reinforced by recent literature like Sethi's 2025 review.
Recommended Treatment Protocols
The BASHH syphilis guidelines 2024 reaffirm penicillin as the first-line treatment for all stages of syphilis, but provide nuanced recommendations based on stage and patient factors.
Key Takeaways: Syphilis Treatment at a Glance
- First-line for Early Syphilis: A single dose of intramuscular Benzathine penicillin G.
- First-line for Late Latent/Tertiary Syphilis: Three weekly doses of intramuscular Benzathine penicillin G.
- Penicillin Allergy: Doxycycline is the recommended alternative, with careful counselling and follow-up.
- Neurosyphilis & Ocular Syphilis: Requires intensive therapy with intravenous aqueous penicillin G for 10-14 days.
- Post-Treatment Follow-up: Essential. Non-treponemal titers (RPR/VDRL) should decline, typically by 4-fold within 6-12 months for early syphilis.
The guidelines stress the importance of the Jarisch-Herxheimer reaction, an acute febrile reaction that can occur within 24 hours of treatment, particularly for early syphilis. Patients should be warned about this possibility, which is a sign of effective treatment but may require symptomatic management.
Special Populations: Pregnancy and Neurosyphilis
Two areas receiving focused attention in the 2024 updates are syphilis in pregnancy and neurosyphilis, both of which have dedicated guideline documents.
Syphilis in Pregnancy
The separate 2024 guideline by Kingston on syphilis in pregnancy and child is a testament to its urgency. Congenital syphilis can cause miscarriage, stillbirth, prematurity, and severe lifelong disability in the newborn. The guidelines mandate:
- Universal Screening: All pregnant individuals should be offered syphilis screening at their first antenatal appointment.
- Prompt Treatment: Pregnant people with syphilis should be treated immediately with penicillin regimens appropriate for their stage of disease. Penicillin is the only therapy known to effectively treat the fetus.
- Careful Follow-up: Serial ultrasound monitoring and post-treatment serological titers are crucial to ensure treatment success and fetal well-being.
"Managing syphilis in pregnancy is a race against the clock. Every day of untreated infection increases the risk to the fetus. The BASHH guidelines provide a clear, actionable pathway to protect both mother and child, making the elimination of congenital syphilis an achievable goal." – Illustrative expert opinion on prenatal care.
Neurosyphilis in 2025 and Beyond
Neurosyphilis, infection of the central nervous system, remains a diagnostic and therapeutic challenge. As discussed in Sethi's 2025 review, it can present with subtle symptoms like headache or personality change, or more severe manifestations like stroke or dementia. The BASHH syphilis guidelines clarify indications for lumbar puncture and insist on aggressive IV penicillin treatment for confirmed cases. This highlights the disease's potential for serious involvement beyond its initial presentation.
Prevention, Partner Notification, and Follow-up
Effective management extends beyond the individual patient. The guidelines provide robust frameworks for public health measures.
- Partner Notification (Contact Tracing): For early infectious syphilis, all sexual partners from the last 3 months (primary) to 2 years (secondary/early latent) should be notified, tested, and offered epidemiological treatment.
- Health Promotion & Safer Sex: The guidelines advocate for comprehensive sexual health education, promoting condom use and regular STI testing, especially for those with new or multiple partners. Integrating sexual wellness into overall health is key; exploring resources and products that enhance safe intimacy, like our curated sexual health products, can be part of a proactive approach.
- Serological Follow-up: This is non-negotiable. Patients must have repeat blood tests at 3, 6, and 12 months post-treatment (and longer for late syphilis) to ensure a successful response, indicated by a falling RPR/VDRL titer.
Frequently Asked Questions (FAQ)
What is the main change in the 2024 BASHH syphilis guidelines?
The 2024 update consolidates and refines recommendations based on the latest evidence, with heightened emphasis on managing syphilis in pregnancy (through a separate dedicated guideline) and providing clearer pathways for investigating potential neurosyphilis, reflecting the evolving epidemiology and clinical challenges.
How is syphilis diagnosed according to BASHH?
Diagnosis relies on a combination of serological blood tests: a treponemal test (e.g., EIA) to confirm exposure and a non-treponemal test (e.g., RPR) to assess disease activity and stage. This is combined with a detailed clinical history and examination to look for signs of primary or secondary infection.
What is the treatment for early syphilis?
For early (primary, secondary, and early latent) syphilis, the first-line treatment recommended by BASHH is a single intramuscular injection of Benzathine penicillin G. This is highly effective at curing the infection and preventing transmission.
I'm allergic to penicillin. How can I be treated?
For non-pregnant patients with a penicillin allergy, the guidelines recommend a 14-day course of oral doxycycline. However, follow-up is crucial to ensure treatment success. Desensitization to penicillin is the preferred approach for pregnant individuals or those with neurosyphilis due to doxycycline's limitations in these scenarios.
Why is follow-up testing so important after treatment?
Follow-up blood tests (typically measuring the RPR or VDRL titer) are essential to confirm the treatment worked. A successful response is shown by a 4-fold (or greater) drop in titer within 6-12 months for early syphilis. Without this confirmation, treatment failure or reinfection cannot be ruled out.
How can I practice safer sex and reduce my risk?
Consistent and correct use of condoms during vaginal, anal, and oral sex significantly reduces the risk of syphilis transmission. Regular STI screening, especially if you have new or multiple partners, is vital for early detection. Open communication with partners about sexual health and maintaining a holistic view of wellness, which can include using quality products from trusted sources like vibrators designed for safety, are all key components.
Conclusion
The 2024 BASHH syphilis guidelines represent a critical tool in the modern fight against a resurgent infection. By providing clear, evidence-based protocols for diagnosis, staging, treatment, and public health management, they empower healthcare professionals to deliver optimal care. For the public, understanding the importance of regular screening, recognizing potential symptoms, and engaging fully with treatment and partner notification processes are vital steps. Syphilis is a serious but treatable disease. Through education, destigmatization, and adherence to expert guidelines like those from BASHH, we can work towards better individual health outcomes and a reduction in the population-wide spread of this infection. Your sexual health is an integral part of your overall wellbeing—stay informed, get tested regularly, and seek care promptly if you have any concerns.
Last updated March 28, 2026
References
- Kingston M (2024). BASHH UK guidelines for the management of syphilis 2024.. PubMed:39270129
- Kingston M (2024). British Association of Sexual Health and HIV (BASHH) UK guidelines for the management of syphilis in pregnancy and child. PubMed:39308221
- Sethi V (2025). Neurosyphilis in 2025.. PubMed:40605685